Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT03472157

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

Led by University Hospital, Lille · Updated on 2026-04-22

100

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Lille

Lead Sponsor

M

Ministry of Health, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² \> BMI ≥ 30 kg/m²) with NASH complicated of advanced fibrosis (F3 and F4 fibrosis grade according to Brunt score).

CONDITIONS

Official Title

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide written informed consent and agree to comply with the study protocol prior to enrollment
  • For F3 fibrosis patients: BMI greater than or equal to 30 and less than 35 kg/m²; Fibroscan at least 9 kPa or FibrometreVM at least 0.526 predicting F3 fibrosis within 1 month before inclusion, or F3 diagnosed by liver biopsy before inclusion
  • For F4 fibrosis patients: BMI greater than or equal to 30 and less than 50 kg/m²; Fibroscan at least 15 kPa predicting F4 fibrosis within 1 month before inclusion, or F4 diagnosed by liver biopsy before inclusion
  • Fibroscan at least 9 kPa or FibrometreVM at least 0.526 predicting F3 or F4 fibrosis within 1 month before inclusion, or F3 or F4 diagnosed by liver biopsy before inclusion
  • Agree to have one liver biopsy during screening and one at the end of treatment for assessment
  • For patients with cirrhosis: platelets over 125,000; prothrombin time over 80%; albumin over 35 g/L; MELD score less than 9; Child-Pugh score less than 6; no history of decompensation; no oesophageal varices; no vascular shunt; ASA score 3 or less; alcohol consumption below 20 g/day for women and 30 g/day for men
  • Hypertension must be controlled by stable medication dose for at least 2 months prior to screening
  • Female participants must be non-childbearing (surgically sterilized or postmenopausal) or using effective contraception
  • Agree to attend study visits within the scheduled timeframes
Not Eligible

You will not qualify if you...

  • Previous bariatric surgery except gastric ring removed more than 3 years ago
  • Decompensated cirrhosis with MELD above 7 or Child-Pugh above 5, or history of decompensation (encephalopathy, ascites, jaundice, varicose vein rupture)
  • Hepatocellular carcinoma
  • Platelets below 125,000; prothrombin time below 80%; bilirubin below 20 mmol/L; albumin below 35 g/L
  • Other liver diseases such as excessive alcohol use, hepatitis B or C, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency
  • Active cancer treatment (chemotherapy, radiotherapy, hormone therapy)
  • HIV positive status
  • Recent cardiovascular events within 6 months such as stroke, myocardial infarction, or angina
  • Severe chronic respiratory or cardiac insufficiency (NYHA grade III or IV)
  • Pregnant or breastfeeding women
  • Participation in another clinical trial
  • Drug abuse within the past year
  • Contraindication to bariatric surgery
  • Use of excluded bariatric surgery techniques like gastric banding or biliopancreatic diversion
  • History of cancer not in remission for at least 5 years, except certain skin or cervical cancers treated and believed cured

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hôpital Claude Huriez, CHRU

Lille, France

Actively Recruiting

Loading map...

Research Team

P

Philippe Mathurin, MD,PhD

CONTACT

G

Guillaume Lassailly, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients | DecenTrialz